Skip to Content

News Releases

Aug 15 2022
SomaLogic Reports Second Quarter 2022 Financial Results
Second quarter 2022 revenue of $14.1 million, bringing year to date revenue to $37.1 million. Reducing 2022 revenue guidance to $80-90 million to account for ongoing variability in core service business, macroeconomic and commercial factors. Maintaining substantial cash, cash equivalents, and
Jul 26 2022
SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan® Assay
Brings differentiated miniaturization technology, scientific and engineering expertise, and enhanced ease-of-use capabilities to SomaLogic’s platform while expanding footprint to San Diego, CA BOULDER, Colo. and SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI
Jul 25 2022
SomaLogic to Announce Second Quarter 2022 Financial Results
BOULDER, Colo. , July 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding audio
Jun 13 2022
SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics
BOULDER, Colo. and BINYAMINA, Israel, June 13, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy.
Jun 01 2022
SomaLogic Announces June Conference Participation
BOULDER, Colo., June 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following conferences. Jefferies Healthcare Conference June 8-9, 2022, in New York 7th Annual MarketsandMarkets
May 12 2022
SomaLogic Reports First Quarter 2022 Financial Results
Company to host conference call today at 4:30 p.m. ET BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. “Our successful first quarter has kickstarted another
Apr 21 2022
SomaLogic to Announce First Quarter 2022 Financial Results
BOULDER, Colo., April 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. Company management will host a corresponding
Apr 12 2022
Major journal publishes landmark proteomics study demonstrating development of an unprecedented new clinical cardiovascular risk test
SomaScan® platform study utilizing 32,000 samples showed a 27-protein test is a uniquely superior surrogate for cardiovascular outcomes BOULDER, Colo., April 12, 2022 (GLOBE NEWSWIRE) -- In one of the largest proteomic studies ever conducted and published April 6 in the journal Science
Mar 29 2022
SomaLogic Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth quarter 2021 revenue of $23.0 million contributed to record full year revenue of $81.6 million, 46% growth over the prior year Established over 75 new customer accounts, expanding and diversifying revenue base Substantial cash and investments of $657.7 million at year-end Maintaining 2022
Mar 21 2022
SomaLogic to provide 210 million protein measurements to EPIC researchers to better understand and predict cancer development
BOULDER, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the European Prospective Investigation into Cancer and Nutrition (EPIC) study beginning in the first quarter
Displaying 1 - 10 of 19